Report
EUR 14.17 For Business Accounts Only

SUMITOMO DAINIPPON PHA. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of SUMITOMO DAINIPPON PHA. (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date February 1, 2022, the closing price was JPY 1,175.00 and its target price was estimated at JPY 1,102.04.
Underlying
Sumitomo Dainippon Pharma Co. Ltd.

Sumitomo Dainippon Pharma is engaged in the manufacture, sale/purchase, and import/export of pharmaceuticals, food additives, veterinary products, diagnostic agents and research materials. Pharmaceutical segment manufactures and sells medical and general pharmaceuticals including hypertension and angina drugs, digestive tract function prokinetic agents, peripheral circulation stimulant, and carbapenem antibiotics. Other business segment manufactures, purchases and sale of veterinary medicines, food additives, industrial chemicals, extracts, diagnostic drugs and materials for research and inspection; purchases and sells feed and feed additives.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch